Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Rxi Pharmaceuticals (RXII)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,445
  • Shares Outstanding, K 4,380
  • Annual Sales, $ 20 K
  • Annual Income, $ -12,450 K
  • 36-Month Beta 2.07
  • Price/Sales 96.28
  • Price/Cash Flow N/A
  • Price/Book 0.83
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.30
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/14/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.10
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.11
  • Prior Year -0.84
  • Growth Rate Est. (year over year) +88.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.31 +6.45%
on 11/15/18
0.50 -34.00%
on 11/08/18
-0.12 (-26.67%)
since 10/16/18
3-Month
0.31 +6.45%
on 11/15/18
2.19 -84.93%
on 09/27/18
-1.19 (-78.29%)
since 08/16/18
52-Week
0.31 +6.45%
on 11/15/18
7.70 -95.71%
on 11/29/17
-5.37 (-94.21%)
since 11/16/17

Most Recent Stories

More News
Report: Exploring Fundamental Drivers Behind Pluristem Therapeutics, RXi Pharmaceuticals, Saga Communications, Global Self Storage, Sequential Brands Group, and Finjan -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Pluristem Therapeutics,...

RXII : 0.33 (unch)
SQBG : 1.16 (+4.50%)
SELF : 3.98 (+0.76%)
SGA : 33.70 (+0.45%)
PSTI : 1.01 (-0.98%)
FNJN : 3.34 (+1.21%)
4 Healthcare Stocks To Watch On Wednesday

CORAL GABLES, FL / ACCESSWIRE / November 14, 2018 / demand is increasing as an aging population continues to drive new growth. The connection between healthcare goods and services is less tied to the...

RXII : 0.33 (unch)
VKTX : 9.03 (-0.44%)
PRPO : 0.18 (unch)
RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic...

RXII : 0.33 (unch)
RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer at SITC 2018

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic...

RXII : 0.33 (unch)
RXi Pharmaceuticals to Webcast Third Quarter 2018 Financial Results on Wednesday, November 14, 2018

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic...

RXII : 0.33 (unch)
RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone(TM) for the Treatment of Common Warts

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic...

RXII : 0.33 (unch)
RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics with Iovance's Tumor Infiltrating Lymphocytes (TILs) for Solid Tumors

RXi Pharmaceuticals Corporation (NASDAQ: RXII) announced today that it has entered into a research collaboration with Iovance Biotherapeutics to evaluate the potential synergies with RXi's novel sd-rxRNA...

RXII : 0.33 (unch)
RXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate Highlights

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic...

RXII : 0.33 (unch)
RXi Pharmaceuticals Announces Presentation at the 2018 New York Oncology Investment Conference

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic...

RXII : 0.33 (unch)
RXi Pharmaceuticals to Webcast First Quarter 2018 Financial Results on Thursday, May 10, 2018

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic...

RXII : 0.33 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade RXII with:

Business Summary

RXi Pharmaceuticals Corporation is a biotechnology company focused on discovering, developing and commercializing therapies based on its RNAi platform. The Company is developing RXI-109, which is used for the reduction of dermal scarring in planned surgeries, as well as reduces the expression of connective...

See More

Key Turning Points

2nd Resistance Point 0.34
1st Resistance Point 0.33
Last Price 0.33
1st Support Level 0.32
2nd Support Level 0.32

See More

52-Week High 7.70
Fibonacci 61.8% 4.88
Fibonacci 50% 4.01
Fibonacci 38.2% 3.13
Last Price 0.33
52-Week Low 0.31

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar